SAB BIOTHERAPEUTICS, INC. Increase (Decrease) in Prepaid Expense and Other Assets
SAB BIOTHERAPEUTICS, INC. (SABS) reported Increase (Decrease) in Prepaid Expense and Other Assets of -$893.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was -$1.19M, a 554.43% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $297.26K, a 2.13% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was $6.86M, a 612.67% increase year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was -$2.13M, a 8347.45% decline year-over-year.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $5.29M, a 795.11% increase from fiscal 2024.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2024 was $590.46K, a 12.77% increase from fiscal 2023.
- SAB BIOTHERAPEUTICS, INC. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $523.61K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | -$1.19M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$893.00K 10-Q · filed 2026-08-06 | $5.97M derived: sum of 3 quarters · filed 2026-08-06 | $3.84M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $297.26K 10-Q · filed 2026-05-12 | $7.16M derived: sum of 2 quarters · filed 2026-05-12 | $5.03M derived: sum of 3 quarters · filed 2026-05-12 | $5.29M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $6.86M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.73M derived: sum of 2 quarters · filed 2026-03-09 | $4.99M derived: sum of 3 quarters · filed 2026-08-06 | $5.29M 10-K · filed 2026-03-09 | |
| 2025-09-30 | -$2.13M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$1.87M derived: sum of 2 quarters · filed 2026-08-06 | -$1.58M 10-Q · filed 2025-11-14 | -$614.80K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $261.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $553.00K 10-Q · filed 2026-08-06 | $553.28K 10-Q · filed 2025-08-07 | $1.52M derived: sum of 3 quarters · filed 2026-08-06 | $1.54M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $291.07K 10-Q · filed 2026-05-12 | $1.25M derived: sum of 2 quarters · filed 2026-05-12 | $1.28M derived: sum of 3 quarters · filed 2026-05-12 | $592.00K derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $963.01K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $988.85K derived: sum of 2 quarters · filed 2026-03-09 | $300.92K derived: sum of 3 quarters · filed 2026-03-09 | $590.46K 10-K · filed 2026-03-09 | |
| 2024-09-30 | $25.84K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$662.09K derived: sum of 2 quarters · filed 2025-11-14 | -$372.55K 10-Q · filed 2025-11-14 | $1.04M derived: sum of 4 quarters · filed 2025-11-14 | |
| 2024-06-30 | -$687.93K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$398.39K 10-Q · filed 2025-08-07 | $1.01M derived: sum of 3 quarters · filed 2025-08-07 | $782.91K derived: sum of 4 quarters · filed 2025-08-07 | |
| 2024-03-31 | $289.54K 10-Q · filed 2025-05-09 | $1.70M derived: sum of 2 quarters · filed 2025-05-09 | $1.47M derived: sum of 3 quarters · filed 2025-05-09 | $1.13M derived: sum of 4 quarters · filed 2025-05-09 | |
| 2023-12-31 | $1.41M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $1.18M derived: sum of 2 quarters · filed 2025-03-31 | $842.51K derived: sum of 3 quarters · filed 2025-03-31 | $523.61K 10-K · filed 2025-03-31 | |
| 2023-09-30 | -$230.56K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | -$569.35K derived: sum of 2 quarters · filed 2024-11-06 | -$888.25K 10-Q · filed 2024-11-06 | ||
| 2023-06-30 | -$338.79K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$657.69K 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$318.90K 10-Q · filed 2024-05-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |